Shared decision-making in prostate cancer treatment: selecting an androgen deprivation therapy option Authors: Sean P. Collins, Martine C. Maculaitis, Marty Chakoian Published: 2026 ABSTRACT ABSTRACTThis podcast will provide an overview of androgen deprivation therapy (ADT) for advanced prostate cancer, including the different treatment options currently available. The podcast will also cover the key results of recently published studies that looked at patient preferences for different characteristics of ADT. Additionally, a physician and patient will each discuss the importance of shared decision-making in selecting the optimal ADT option. They will address key factors to discuss when evaluating ADT options, and emphasize the importance of aligning treatment choices with patients’ individual needs and the best available scientific evidence. Podcast discussion Dr. Sean Collins: Hello, my name is Dr. Sean Collins and I am joined by Dr. Martine Maculaitis and Marty Chakoian. I am a Professor of Radiation Oncology who specializes in the care of men with prostate cancer at the University of South Florida in Tampa. Dr. Maculaitis is a psychologist with over 15 years of experience in public health, patient-reported outcomes, and real-world evidence research. Marty is a 22‑year prostate cancer survivor, a patient advocate, a support-group leader, and the Chair of the Pacific Northwest Prostate Cancer SPORE Patient Advocates Committee, which is a really important committee. Thank you guys for joining us! It is my pleasure to moderate this podcast discussion titled “Shared decision-making in prostate cancer treatment: Selecting an androgen deprivation therapy option.” This work, including medical writing and editorial assistance, was funded by Pfizer Inc. in collaboration with Sumitomo Pharma America, Inc. All funding and disclosure information is available on the article homepage at Taylor and Francis Online. I’m going to get us started by doing an overview of androgen deprivation therapy for advanced prostate cancer, just so we’re all on the same page. Androgen deprivation therapy—also referred to as ADT—is a treatment for advanced prostate cancer that decreases the level of male hormones, such as testosterone, which can help slow the growth of prostate cancer cells [1]. Medical guidelines recommend ADT for patients with metastatic disease as well as some forms of non-metastatic disease, such as intermediate-risk or high-risk localized cancer receiving radiation therapy [2,3]. The currently available ADT options include surgical castration, removal of the testicles to stop the production of testosterone; but more commonly used is medical castration, use of medications to lower testosterone levels without surgery. The medical castration options include gonadotropin-releasing hormone—but we call it GnRH—agonists, such as leuprolide [1], and GnRH antagonists, such as degarelix or relugolix [1,2]. Side effects vary among ADTs, but side effects include things like hot flashes, reduced sexual desire or libido, erectile dysfunction, fatigue, generalized pain, weight gain, loss of muscle mass, bone thinning—or also called osteoporosis—and joint problems. Importantly, hormone therapy may also increase the risk of heart disease and diabetes [1,3]. Currently available medical ADT options approved by the US Food and Drug Administration, or the FDA, for the treatment of prostate cancer differ in key treatment-related characteristics. So, the first one is administration, like how you get the injection or the pill? How often is it taken? Like, do you take it once a day? Do you take it twice a day? Do you get injections once a month? Once every three months? And where do you take it? At home or in a doctor’s office? GnRH agonists and the GnRH antagonist degarelix are administered as regular injections in the muscle or under the skin, or implants under the skin at the doctor’s office. Leuprolide is commonly given every 1, 3, 4, or 6 months, and degarelix is commonly given every month [1]. Relugolix is the only option that can be taken as a once-daily pill at home and was approved by the US FDA in 2020 for use in adults with advanced prostate cancer [4,5]. A second important factor is out-of-pocket cost—how much does this treatment actually cost the patient—which is critically important [6]. Also, management of testosterone surges is different. GnRH agonists can cause testosterone levels to increase in the first month of treatment, while GnRH antagonists do not cause this issue [1,2]. Patients who receive GnRH agonists may need to take an additional medication at the start of their treatment to mitigate the consequences of the testosterone surge [2]. Sexual interest is an important factor when deciding about hormonal therapy [6,7]. Testosterone recovery—how long a time it takes for testosterone to come back after you finish the medication [6,7]. So, another important side effect of ADT is the cardiovascular risk [6,7], that is the chance of heart or blood vessel problems. In patients with prostate cancer, treatment with ADT is associated with an increased risk of cardiovascular events, with some evidence suggesting that the risk may be higher for GnRH agonist options compared with antagonist options [8]; though, the evidence is not conclusive. There was a meta‑analysis that concluded that limitations in the number and quality of studies prevented researchers from having a definitive answer on the cardiovascular risks of agonists versus antagonists [8]. So, this is still an important issue that needs to be studied. So, hopefully I did a good job summarizing, but what we’re really here for is to hear about Dr. Maculaitis’s research describing what are patients’ preferences for attributes of ADT. So, I’m excited to hear about this, do you want to go on? Dr. Martine Maculaitis: Oh, that’d be great. Thank you so much and happy to talk about our research. So, in the study that we ran [6,7], we asked US patients with prostate cancer to complete a self-report survey. We collected the data from February to July of 2022, and we aimed to understand which ADT characteristics are most important to them and how their preferences vary with respect to different groups of patients. So, our survey asked the patients to choose between a series of two hypothetical ADT treatment options with varying levels of each characteristic. So, we recruited the patients to join the study through a variety of means including e-mail, e-newsletters, and so forth, and this was done through the Kantar Profiles online consumer panel. One key thing to kind of point out here is—as a self-reported web-based survey—it’s possible that some groups of patients may have been underrepresented, including those in rural areas who may have inadequate internet access, those who are institutionalized, or those with severe disabilities. Additionally, while the hypothetical treatment options in our study were based on a review of the literature and input from clinical experts, as with all self-report studies, they may not perfectly align with real-world decisions [6,7]. Furthermore, our study surveyed US‑based patients only, and so it’s possible our studies may not generalize to patients in other countries. So, our study sample included 304 males, the majority of whom were age 65 years or older [6,7]. In the overall sample in our study, the patients rated out-of-pocket costs, mode of administration, and impact on sexual interest as the most important factors in their treatment decisions, with patients generally preferring a daily pill over less-frequent injections. Risk of cardiovascular issues, needing to take medication to mitigate consequences of a T [testosterone] surge after starting treatment, and T recovery after stopping treatment were the least important [7]. So, the study compared ADT preferences among subgroups that were based on cancer stage, so localized versus advanced; race/ethnicity, so White patients versus those of any other race/ethnicity; cardiovascular comorbidities, those with one or more versus those with none; age, so under 65 versus 65 or older; and ADT experience, so those currently using ADT or previously treated with ADT versus those who have never used ADT. Similar to the overall sample, the patients across all the subgroups preferred a once-daily ADT pill over less-frequent injections. We also found, interestingly, that preference for that oral, daily pill was stronger for patients who had advanced prostate cancer versus those with localized disease; racial and ethnic minorities versus their White counterparts; and patients who had cardiovascular comorbidities versus those who did not [7]. So, some limitations to keep in mind here [are] that the analysis did not explore differences in preferences between racial and ethnic minority groups; so, for example, Black and Latino or Hispanic patients. Furthermore, in our study, White patients were slightly overrepresented, while Hispanic or Latino patients were slightly underrepresented relative to the US overall population [7]. So, one area of future study that would be necessary here is to look at the impact of race on patient ADT preferences. So, a separate analysis we conducted using the same sample, we actually found that we could put patients into four different distinct groups based on the characteristics of ADT that they preferred [6]. So, we found that three of the groups had one single characteristic that the patients considered to be most important. So one group, we referred to as the “cost-sensitive” group, and they primarily favored lower out-of-pocket costs for treatment. Another group, we referred to as the “sexual interest” group, and they had a very strong preference to have lower impact on sexual interest. And we had another group, we referred to as “favors daily pill,” and these patients strongly prefer a daily pill over infrequent injections. So the fourth group, which we referred to as the “favors injection” group, those patients did not have a single characteristic that was predominantly important to them. Rather, these patients rated three characteristics as being similarly important to their treatment preferences. Specifically, this group preferred to have lower out-of-pocket costs, less frequent injections; these patients also preferred to have a lower chance of achieving normal T levels after stopping treatment. And it’s possible that that preference may have been because these patients believe that higher T levels may increase the risk of their prostate cancer returning or worsening [6]. So other research conducted by a different group, it was another survey-based study [9]. This was conducted in the UK among 48 ADT-experienced patients with prostate cancer. That study found that the most important attributes to those patients included that the ADT was an established therapy, administered via injection every 3 months, had more rapid T recovery post treatment termination, and have more rapid onset of action, and be taken orally; and their preference was in that order. So, notably, in that UK study when the participants were asked to rank 5 blinded treatments based on real ADT profiles, relugolix was the preferred option of 63% of the respondents. The most common reason they provided for choosing it was that it could be taken orally [9]. So, that was a recap of the research that we’ve done in this area and I’d like to now pass it over to Dr. Chakoian to discuss shared decision-making. Marty Chakoian: Thank you, Dr. Maculaitis. I have to start by saying I’m not a doctor, I’m just a patient and patient advocate. But I have a lot of interest in this and I’m very excited about this work. And the choices that you’ve described seem like a perfect platform for shared decision-making between patients and their clinical team. So, as we all know, shared decision-making is a collaborative approach in healthcare where the patient, the physician, sometimes even the caregivers, work together to make decisions that align with the patient’s preferences, and the patient’s individual needs, and the patient’s values within the scope of multiple acceptable treatment options from a clinical standpoint [10,11]. The American Urological Association guidelines even recommend shared decision-making for some aspects of urological care [10]. I think it’s important to remember that shared decision-making isn’t achieved with one clinical visit. It’s really an ongoing discussion between the physician and the patient throughout the treatment journey; it’s a relationship, and that relationship has to be based on mutual trust and respect. The goals of shared decision-making and the process around it are really just to enhance the quality of the medical decisions, to ensure that patients are better informed and more satisfied with their care, and potentially that leads to improved clinical outcomes [10,12]. So, while shared decision-making can provide these benefits, it’s important to remember that there are barriers to implementation. Those can include physician time constraints and sometimes lack of training, as well as a reluctance by patients to make healthcare decisions, sometimes due to what we feel is our limited health literacy or lack of knowledge or just lack of confidence [10]. Fortunately, there are a variety of tools to aid in the shared decision-making process and for more information about that for healthcare providers, they can visit the American Urological Association’s webpage, which appropriately is titled “Implementation of Shared Decision Making into Urological Practice” [10]. So that’s, you know, from the patient’s perspective. Dr. Collins, what does that look like from the physician’s side? Dr. Sean Collins: So, the physician’s role in shared decision-making is that I have to provide complete and balanced information about the treatment options and potential outcomes. All doctors are biased, but I have to give the options in a way that I, you know, explain them, so that the patient can actually choose what’s right for them, not what I want them to do. I have to communicate clearly. I have to ensure that they understand—like, I mean, not every patient is going to have a college education—so, I have to speak in language that clearly explains the options to them. I need to hear what their preferences are and help them weigh the benefits and the risk of each choice, because, you know, how would they know? They haven’t experienced it. I have been taking care of patients for 20 years, so to me I know what the true risks and benefits of these treatments are, and I have to make sure that I understand what their needs are so I can help them align the treatments to their needs. Marty, what’s the patient’s role in shared decision-making? Like, what do you do when you’re making your decisions for your personal care? Marty Chakoian: Yeah, that’s a great question. So, you know, the way I see it and the way I counsel the patients in my support group, the patient’s role really involves actively participating in the decision-making process every step of the way. And that, for us as patients, that starts with expressing our needs, our values, our preferences, our concerns about all of the treatment options. And we have to ask questions to clarify any doubts or confusions that we have, ensure that we really understand the information provided by the physician; and if we don’t understand it, we have to ask follow-up questions. We also want to consider how each option aligns with our individual values, our needs, our lifestyle, and then communicate that back to the physician so that we can have a meaningful conversation around the pluses and minuses of each of those options. Dr. Sean Collins: Tell us about it from the patient perspective. Marty Chakoian: Sure. So, you know, the mode of administration, that’s important to patients. Some of us maybe prefer a daily oral pill because we can take that anywhere we want at any time, and we’d avoid the needles and the injections and all of that stuff. But there are patients who prefer to have that monthly or 3-month injection because that’s something that you schedule and you don’t have to keep repeating it on a on a daily basis [13]. Those differences might seem clear, but actually it’s a little more subtle and more complicated than that. So, for example, if I were going to take the daily pill, I would want to know what if I forget? You know, what if I miss a pill one day? Should I take two pills the next day or just go back to a regular daily routine? Similarly, what if something interrupts my schedule for my injection? How long do I have before that starts to really have a negative impact on my health? So, having the physician provide that information and to talk that through with me as a patient, I think is really important. Additionally, as you mentioned, the GnRH agonist options can cause testosterone levels to spike, and that can have issues around bone pain, urinary problems [2], and so, I need to know that I might need to take some additional medicine at the start of treatment to mitigate the consequences of the testosterone surge. Cost is a big deal for patients. These different medications may have different costs—well, in fact, they do—and that’s not only the cost of the medication itself, administration, the management of side effects, and that varies from patient to patient. And it also really is dependent on the patient’s insurance [14]. So, that kind of discussion needs to be part of the decision-making. You mentioned earlier sexual interest and function, and for many patients that’s really a critical factor [7]. So, that’s important for physicians and patients to have that conversation. Are we sexually active? Do we plan to be sexually active? And how do the different options affect that? What are the potential interventions and supportive measures that can be available? You mentioned time to testosterone recovery and that’s also different depending on the different mechanism of the agent. And so, you know, that’s something to discuss with patients as well, so the patients understand what that means and what that can do to quality of life, what the side effects are, and we can have really clear expectations. There’s cardiovascular risk that that is associated with some of these agents, and so physicians and patients need to discuss how to monitor that, what preventive strategies are available to us, and how do we make sure that we minimize or mitigate those cardiovascular risks [8]. And then other side effects, anybody who has been on ADT knows that, you know, the side effects include the hot flashes, fatigue, general pain, weight gain, loss of muscle mass, osteoporosis, joint problems, and that affects quality of life on a daily basis for many patients [1]. We need to understand how those side effects are associated with these agents and, again, what management strategies might exist for us to mitigate those. So, those are some of the things that patients care about and really need to have an honest discussion with their physician as we go into these therapies. Dr. Sean Collins: So, I’m going to try to summarize the key takeaways. You guys can chime in if you don’t agree with me or if you have something to add. A key takeaway is that Dr. Maculaitis’s research suggests that the majority of patients prefer a prostate cancer treatment that is taken as a daily pill at home over less‑frequent injections at the doctor’s office. This was observed across the overall sample and all subgroups. To me, injections hurt and sometimes they hurt for a while afterward. And that’s, you know, these patients vary. I mean, poor, underserved people might have different priorities than rich White people, right? So to me, we have to take this into consideration; costs are important. My key takeaway is it’s not just about survival; like, this is a person’s life. Most of our patients are older, and they have different priorities, and we need to take those priorities into account. It’s not good enough anymore for the doctor just to make a recommendation and make, you know, force the patient to follow it. And importantly, I would say that the research we’re discussing today has made me a better doctor. I mean, when I think about patient preferences now, like every time I see a patient, I think about this research and how I have to treat every patient as an individual with, you know, and let them decide what they want, not what I want them to do. And we really have to, you know, make sure that everybody’s involved. I liked what you brought up earlier, Marty, is that caregivers are important too. I think caregivers do a large amount of work taking care of patients and what’s important to them should be important to us too. Caring for someone who is sick is not easy, it takes away from your life; so their voice should be heard too. So, do you guys have anything to add about key takeaways? Marty Chakoian: I really appreciate what you said about caregivers. You know, it’s sort of a cliche, but it’s so true that prostate cancer is a disease that affects the whole family and especially the relationship between the patient and his partner. And so, yeah, that definitely needs to be part of the equation. Thank you for that. Dr. Sean Collins: I want to personally thank Dr. Maculaitis. There aren’t many MDs that are capable of doing this kind of detailed analysis, and I think she’s really helped me as a doctor, be a better doctor. And I think she’s helped Marty actually be able to speak to the doctor, you know, and have the power to voice his opinion about what he wants, not what the doctor wants. So, thank you very much. Dr. Martine Maculaitis: Thank you. The pleasure is mine. Marty Chakoian: Thank you. Dr. Martine Maculaitis: It’s incredibly important to make sure that patients are getting the treatment that is both optimal for their health but also aligned with their preferences, needs, and values. Supplementary Material Supplemental Material Supplemental Material